STOCK TITAN

Lite Strategy (LITS) 10-K Filings

LITS NASDAQ

Ticker history: MEIP became LITS (Lite Strategy, Inc.) on . Earlier news and filings retain their original names and dates. View MEIP history.

Here are the 10-K annual reports from Lite Strategy, Inc. (LITS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow LITS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LITS filings page.

Rhea-AI Summary

Lite Strategy, Inc. reported a fiscal 2026 net loss of $71.150 million, compared with $15.945 million in fiscal 2025, while pursuing a Litecoin treasury strategy and pre-clinical drug development. The $54.408 million change in fair value of digital assets included unrealized remeasurement losses and realized losses on collateral transfers and LTC sales. At June 30, 2026, cash and cash equivalents were $5.706 million and digital assets were $27.272 million; management believes those balances will fund operations for at least 12 months from issuance of the financial statements.

The company closed a $100.0 million PIPE on July 22, 2025, issuing 23,216,898 shares at $3.42 per share and pre-funded warrants for up to 6,022,869 shares at $3.4199 per warrant. Through June 30, 2026, it repurchased 4,378,525 shares at a weighted-average $1.12 per share, leaving approximately $20.2 million of its $25.0 million authorization available. The treasury strategy includes covered call options on some LTC holdings, with collateral potentially delivered if exercised. Voruciclib pre-clinical work in nononcologic indications began in fiscal 2026. The auditor's report highlighted risks related to Litecoin volatility and custody.

Rhea-AI Summary

Lite Strategy, Inc. (filing excerpts) discloses equity plan details, leadership changes, executive pay and severance terms, option activity, license and contingent payment obligations, and committee responsibilities. The company has omnibus and inducement equity plans authorizing 1,850,739 and 217,000 shares respectively, with specific option pools and weighted-average exercise prices reported. Leadership changes included resignations of the CEO and CMO effective August 1, 2024, with separation agreements providing severance, COBRA and accelerated vesting; one former CEO received $614,000 severance. Justin J. File became Acting CEO (in addition to CFO) and received total annual compensation of $912,667 and a $275,000 annual incentive plus a $96,000 success fee tied to cash retention. The filing notes cashless exercises and warrant conversions totaling millions of shares issued and lists committee charters and oversight duties for audit, compensation and nominating committees.